Seven Fleet Capital Management LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV

Seven Fleet Capital Management LP acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, HoldingsChannel reports. The fund acquired 128,168 shares of the company’s stock, valued at approximately $3,550,000. Roivant Sciences accounts for 1.1% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 22nd biggest holding.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA boosted its stake in shares of Roivant Sciences by 790.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after buying an additional 2,052,693 shares during the last quarter. Capricorn Fund Managers Ltd increased its position in Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after acquiring an additional 247,000 shares during the last quarter. Vanguard Group Inc. increased its position in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after acquiring an additional 3,254,113 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock valued at $1,746,000 after acquiring an additional 38,354 shares during the period. Finally, Nicholas Investment Partners LP lifted its holdings in Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after acquiring an additional 34,235 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

ROIV has been the topic of several research reports. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. TD Cowen raised their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Citigroup raised their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.59.

Insiders Place Their Bets

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the completion of the transaction, the director directly owned 13,701,546 shares in the company, valued at $473,388,414.30. This trade represents a 5.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 2,055,913 shares of company stock worth $69,639,633 in the last three months. 10.80% of the stock is owned by company insiders.

Roivant Sciences Trading Down 1.8%

Shares of ROIV opened at $33.91 on Friday. The business’s 50 day moving average is $32.63 and its 200 day moving average is $29.05. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00. The company has a market capitalization of $24.39 billion, a PE ratio of -56.52 and a beta of 1.11.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.